Q1 2026 · 13F-HR
Tri Locum Partners LPholdings as filed
Filed 2026-05-18 · accession 0001826434-26-000004
$712.5M
Reported value
17
Positions
2026-03-31
Period end
The Brief · Tri Locum Partners LP · Q1 2026
AI · grounded in 13F
Tri Locum Partners LP exited its position in DHR for a reduction of $79.4M. The fund established new positions in ISRG for $70.6M, TMO for $65.1M, and VRTX for $57.7M. Other notable activity includes closing positions in BSX and IONS, while increasing its stake in DEXCOM INC by 65.6%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 478160104 | JNJ | JOHNSON & JOHNSON | $101.3M | 14.2% | 414,503 | Common | SOLE |
| 46120E602 | ISRG | INTUITIVE SURGICAL INC | $70.6M | 9.91% | 153,250 | Common | SOLE |
| 883556102 | TMO | THERMO FISHER SCIENTIFIC INC | $65.1M | 9.13% | 132,413 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $58.4M | 8.20% | 255,332 | Common | SOLE |
| 92532F100 | VRTX | VERTEX PHARMACEUTICALS INC | $57.7M | 8.10% | 129,314 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $56.8M | 7.98% | 61,795 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $54.1M | 7.59% | 103,288 | Common | SOLE |
| 252131107 | DXCM | DEXCOM INC | $43.8M | 6.15% | 698,158 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $41.7M | 5.86% | 70,370 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $31.6M | 4.44% | 308,506 | Common | SOLE |
| 881624209 | TEVA | TEVA PHARMACEUTICAL INDS LTD | $30.8M | 4.32% | 1,021,008 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $30.0M | 4.21% | 158,663 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $23.1M | 3.24% | 31,635 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $17.7M | 2.49% | 252,588 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $12.2M | 1.71% | 145,543 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC. | $10.5M | 1.47% | 62,116 | Common | SOLE |
| 24477V105 | DFTX | DEFINIUM THERAPEUTICS INC | $7.0M | 0.98% | 369,588 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.